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ABSTRACT
Antiepileptic drugs (AEDs) are used increasingly in clinical practice to treat a number of conditions. However, the relationship between
the use of these medications, particularly the newer AEDs, and fracture risk has not been well characterized. We used data from the
Women’s Health Initiative (WHI) to determine the relationship bewteen the use of AEDs and falls, fractures, and bone mineral density
(BMD) over an average of 7.7 years of follow-up. We included 138,667 women (1,385 users of AEDs and 137,282 nonusers) aged 50 to 79
years in this longitudinal cohort analyses. After adjustment for covariates, use of AEDs was positively associated with total fractures
[hazardratio(HR)¼1.44, 95%confidence interval(CI)1.30–1.61], allsite-specificfracturesincludingthe hip(HR¼1.51, 95%CI1.05–2.17),
clinical vertebral fractures (HR¼1.60, 95% CI 1.20–2.12), lower arm or wrist fractures (HR¼1.40, 95% CI 1.11–1.76), and other clinical
fractures (HR¼1.46, 95% CI 1.29–1.65) and two or more falls (HR¼1.62, 95% CI 1.50–1.74) but not with baseline BMD or changes in BMD
(p .064 for all sites). Use of more than one and use of enzyme-inducing AEDs were significantly associated with total fractures
(HR¼1.55, 95% CI 1.15–2.09 and HR¼1.36, 95% CI 1.09–1.69, respectively). We conclude that in clinical practice, postmenopausal
women who use AEDs should be considered at increased risk for fracture, and attention to fall prevention may be particularly important
in these women.  2010 American Society for Bone and Mineral Research.
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Introduction
W
orldwide, 50 million people suffer from epilepsy, and the
majority use antiepileptic drugs (AEDs).
(1) However,
increasingly, even among those without epilepsy, use of AEDs
is becoming more prevalent.
(2,3) Therefore, the relationship of
AED use to osteoporosis is of interest.
The relationship of AED use to fractures is controversial, with
some,
(4,5) although not all,
(6) studies suggesting that fracture risk
is increased. However, these reports are limited by sample size,
selection of controls, and most important, the failure to take into
accountpotentialconfoundingfactors.
(4,5)Evenalargepharmac-
oepidemiologic database that examined the relationship of AED
use and fractures was unable to control for important potential
confounders, including family history of fractures, smoking
history, and calcium/vitamin D intake,
(7) which are available in
the Women’s Health Initiative (WHI). In addition, most studies of
the relationship of AED use and fractures have excluded racial
groups other than Caucasians.
(6,8) However, epilepsy does not
have a particular racial predilection.
(9) Few studies have included
the non-enzyme-inducing category of these drugs,
(7,10,11) whose
use is increasing rapidly, including for indications other than
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873epilepsy.
(2,3) Finally, fall history has not been well considered in
previous studies of the relationship between AED use and
fracture
There are a number of mechanisms by which AEDs may be
associated with fractures. Vitamin D deficiency may occur with
AEDs,
(12–18) and it has been suggested that enzyme-inducing
AEDs (inducers of the cytochrome P450 enzyme system) in
particular may be associated with vitamin D deficiency because
enzyme induction may lead to increased catabolism of
vitamin D.
(19) In addition, undercarboxylation of the bone Gla
protein osteocalcin, a vitamin K–dependent protein that is a
specific product of the osteoblasts,
(20) has been reported with
AEDs.
(4) This is potentially important because epidemiologic
studies suggest an association between undercarboxylation of
osteocalcin and increased fracture rates.
(21,22) Fall history is
important because falls may be associated with AEDs and/or the
condition for which the AED is prescribed. Dizziness, ataxia, and
unsteady gait are among the most common adverse effects of
AEDs,
(23–27) thereby having an impact on fall risk. Alternatively,
conditions such as seizures
(1) and diabetic neuropathy
(28) are
treated with AEDs, and falls occur as a result of these
conditions.
(29)
No study to date has examined the relationship between AED
use and bone mineral density (BMD) and fractures (including fall
history) within the context of a large prospective study of
ambulatory, multiethnic, noninstitutionalized women that
uniformly collected medication exposure, BMD, and fracture
and fall outcomes. The purpose of this study was to examine the
association between AED drug use and changes in BMD,
fractures, and falls in the WHI, including use of more than one
AED and use of the more recently introduced non-enzyme-
inducing AEDs.
We hypothesized that compared with nonusers, AED users
would have greater loss in BMD, more falls, and more fractures.
Additionally, we hypothesized that users of more than one AED
as opposed to users of one AED would have more fractures and
that there would be more fractures in users of enzyme-inducing
AEDs compared with non-enzyme-inducing AEDs. We suspected
that this would be the case because increased hepatic
catabolism of vitamin D metabolites occurs with enzyme-
inducing AEDs.
(30)
Materials and Methods
Design/setting and participants
We conducted a prospective study of AED use and changes in
BMD (3 years) and fractures and falls (7.7 years) in women aged
50 to 79 years at 40 clinical centers in the WHI from 1993 to 1998.
Users of corticosteroids (n¼1406) and participants with missing
covariate data (n¼21,735) were excluded. The study population
for the fracture outcomes (1385 AED users and 137,282 nonusers
ofAEDs)includedallwomenintheWHIObservationalStudy(OS)
and the WHI Clinical Trials (CT). BMD was available in a subset (84
AED users and 8677 nonusers of AEDs). Details of WHI methods
have been described elsewhere.
(31) All protocols were reviewed
and approved by the institutional review board at each
participating center.
Medication use
Current medication use was ascertained by having the
participants bring the containers with all medications taken
for the prior 2 weeks to the baseline visit and the year 3 visit.
Interviewers entered each medication into the database, which
assigned drug codes using Medispan software (First DataBank,
Inc., San Bruno, CA, USA). Information on duration of use but not
dose was recorded. For this study, we defined hormone therapy
(HT) as use of an estrogen with or without progesterone (oral or
patch formulations). Use of bisphosphonates, calcitonin, and
selective estrogen receptor modulators (SERMS) also was noted.
Current AED use was defined as any use at the baseline and/or at
the year 3 visit. We categorized AEDs into two groups: (1)
enzyme-inducing and (2) non-enzyme-inducing. The category of
enzyme-inducing AEDs included carbamazepine, mephenytoin,
phenytoin, and primidone, and the category of non-enzyme-
inducing AEDs included clonazepam, divalproex sodium,
valproic acid, gabapentin, lamotrigine, methsuxime, and topir-
amate.
(32–34) Since divalproex sodium and valproic acid may be
weakly cytochrome P450 enzyme-inducing and topiramate may
be weakly enzyme-inducing in a dose-dependent manner,
(35)
these medications also were included as enzyme inducers in a
separate sensitivity analysis. In models looking at the number of
AEDs used,AEDusersweresplitintotwogroups,those whoused
only one AED and those who used more than one AED. These
levels of AED use were put into a model along with those who
were not using AEDs. Duration of use of AEDs was examined in
three categories (<2 years, 2 to 5 years, and >5 years).
Dietary supplements
Dietary intake of calcium and vitamin D were measured with a
semiquantitative food-frequency questionnaire.
(36) Vitamin D
intake was defined as the sum of vitamin D from supplements
and diet, whereas calcium intake included all calcium from
medications, supplements, and diet.
Other covariates
Questionnaires were used to collect information on age,
ethnicity, smoking history, parental history of hip fractures,
prevalent fractures on or after age 55, age at menopause, history
of Parkinson’s disease, history of diabetes, history of multiple
sclerosis (MS), history of stroke, and health status. A history of
falls was defined as two or more falls in the year before the
baseline visit. Alcohol consumption was estimated from the
food-frequency questionnaire. Energy expenditure from recrea-
tional physical activity was used to determine physical activity
levels. The 36 Item Short Form Health Survey (SF-36) was used to
calculate a physical function construct (scale 0 to 100), with
higher scores indicating better physical function. Height and
weight were measured in the WHI
(31) and used to calculate body
mass index (BMI). Geographic study sites and trial enrollment
[clinical trials (CTs) or observational study (OS)] were adjusted for
in the statistical analyses. Within the calcium/vitamin D
supplementation trial, adjustments were made for assignments
to placebo versus calcium/vitamin D supplementation. All
covariates were selected pre hoc; of these, age, race, and
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covariates were included in fully adjusted models. All covariates
used were from the baseline visit.
Outcomes and follow-up
Measurement of BMD
BMDs of the total hip, anteroposterior lumbar spine, and total
body weremeasuredatbaseline and year3inparticipants at3of
the 40 clinical centers of the WHI (Pittsburgh, Pennsylvania,
Birmingham, Alabama, and Phoenix/Tucson, Arizona) by dual-
energy X-ray absorptiometry (DXA) using a Hologic QDR
densitometer (Model 2000, 2000þ, or 4500 Fan-beam, Hologic,
Inc., Waltham, MA, USA) Three Hologic phantoms (spine, hip, and
linearity) were exchanged among these three centers and
measured in array mode five times, once each day for five
consecutive days, to assess cross-calibration. Spine, hip, and
linearity phantoms were in close agreement (interscanner
variability < 1.5% for the spine, 4.8% for the hip, and 1.7% for
linearity). We determined change in BMD by AED use category at
these sites from baseline to year 3.
Fracture ascertainment
In WHI CTs, all fracture outcomes were verified by radiology
reports. Radiographs were not obtained to ascertain subclinical
vertebral fractures.
(37) In the WHI OS, only hip fractures, and not
any other fractures, were adjudicated by central review of
radiology reports.
Fall ascertainment
Incident falls were ascertained prospectively using question-
naires asking about the number of times the participant fell
(excluding falls owing to sports) in the interval since the last
medical history update.
Statistical analysis
Descriptive analyses (Tables 1 and 2) were stratified by AED use
at baseline and are presented with the number of participants,
means, and standard deviations in each group for continuous
variables and frequencies with percentages for categorical
covariates. For continuous covariates, a two sample t test was
used to compare between groups, whereas for categorical
variables, a chi-square test was used to assess significance.
Modeling (Tables 3 and 4) was done using Cox proportional
hazards models and includes results both with minimal
adjustment (e.g., age, race/ethnicity, and BMI) and full adjust-
ment (i.e., age, race/ethnicity, BMI, smoking status, alcohol
intake, calcium and vitamin D intake, prevalent fracture at age
55þ, history of falls, bisphosphonate use, past/current use of HT,
SERM use, calcitonin use, age of menopause, physical activity
levels, physical function construct, history of diabetes, history of
stroke, parental history of hip fractures, study site region, self-
reported health, history of MS, and history of Parkinson’s
disease). All proportional hazards models additionally were
adjusted for intervention status in the WHI hormone therapy
(active/placebo/not randomized), dietary modification (inter-
vention/comparison/not randomized), and calcium/vitamin D
(active/placebo/not randomized) trials, as well as enrollment in
the WHI OS (yes/no).
Results for each outcome are presented with event totals,
annualized percentages, and hazard ratios (HRs) with their
corresponding95%confidenceintervals(CIs).Fractureoutcomes
were modeled individually first by any AED use at baseline (users
versus nonusers) and then by duration of AED use at baseline
(see Table 3; stratified into groups of <2years, 2 to 5 years, >5
years versus nonusers).
Subgroup analyses also were performed, duplicating the main
models while separating out users by number and type (see
Table 4) of AED used. A final model was run comparing enzyme-
inducing AED users with non-enzyme-inducing AED users,
excluding the 41 persons who used both enzyme-inducing and
non-enzyme-inducing AEDs.
BMD means by AED use are presented with sample sizes,
means,and standard errors in Table 5. Comparisons between the
means at the initial measurement (baseline), final measurement
(year 3), and the 3-year change in BMD between the AED user
and nonusers groups were done both in minimally and fully
adjusted linear models, modeling the BMD covariate of interest
by baseline AED use and using the baseline covariates listed
earlier for adjustments. All analyses were conducted with SAS
Version 9.1 (SAS Institute Inc., Cary, NC,.USA).
Results
Baseline characteristics and medication use
Our data set included 1385 AED users (including n¼269
carbamazepine; n¼470 clonazepam; n¼110 divalproex sodium;
n¼81 gabapentin; n¼5 lamotrigine; n¼3m e p h e n y t o i n ;n¼3
methsuximide; n¼370 phenytoin; n¼67 primidone; n¼1
topiramate; and n¼6 valproic acid). Baseline characteristics of
the study populationand medicationuse byAED useare shown in
Tables 1 and 2, respectively. In general, AED users were sicker and
had more risk factors for fracture than nonusers (see Table 1).
However, AED users were more likely to be HT,bisphosphonate, or
calcitonon users than were nonusers (see Table 2). Among AED
users, there was no significant association of duration of use of
AEDs with prevalent fractures (data not shown).
Fracture and fall outcomes in whole cohort
Among AED users, the annualized percentage of incident
fractures was 3.35% for total fractures, 0.29% for hip fractures,
0.48% for clinical vertebral fractures, 0.72% for lower arm/wrist
fractures, 2.49% for other clinical fractures, and 7.40% for two or
more falls. In nonusers of AEDs, the respective annualized
percentages for these incident fractures and falls were 2.10%,
0.15%, 0.22%, 0.48%, 1.51%, and 4.29%, respectively (see
Table 3). In models adjusted for age, race/ethnicity, and BMI
and in fully adjusted models, respectively, use of AEDs was
positively associated with total fractures, all site-specific
fractures, and falls (see Table 3). In fully adjusted models, there
was a significant association of duration of use of AEDs and total
fractures, two or more falls, and all site-specific fractures
(p .005 for all), except for hip fractures (p¼.156) (data not
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Antiepileptic users Nonusers
p Value n Mean (SD) or % N Mean (SD) or %
Age at screening, mean (SD) 1385 63.06 (7.34) 137,282 63.22 (7.19) .427
50–59 478 34.5 45,367 33.0
60–69 601 43.4 62,045 45.2
70–79 306 22.1 29,870 21.8
Race/ethnicity .002
White 1212 87.5 114,725 83.6
Black 86 6.2 11,509 8.4
Hispanic 46 3.3 4,889 3.6
Native American 5 0.4 549 0.4
Asian/Pacific Islander 20 1.4 3,769 2.7
Unknown 16 1.2 1,841 1.3
Smoking .002
Never smoked 682 49.2 69,654 50.7
Past smoker 576 41.6 58,279 42.5
Current smoker 127 9.2 9,349 6.8
Alcohol use <.001
Nondrinker 614 44.3 39,542 28.8
Current drinker, <7 drinks/week 662 47.8 81,296 59.2
Current drinker, 7þ drinks/week 109 7.9 16,444 12.0
HT use <.001
Never used 466 33.6 56,639 41.3
Past user 274 19.8 22,680 16.5
Current user 645 46.6 57,963 42.2
Bisphosponate use 43 3.1 2,748 2.0 .004
Calcitonin use 9 0.6 383 0.3 .010
History of falls 352 25.4 16,429 12.0 <.001
History of fracture on/after age 55 242 17.5 17,888 13.0 <.001
Parent with hip fracture after age 40 10 0.7 747 0.5 .371
Self-reported health status <.001
Excellent 110 7.9 23,988 17.5
Very good 432 31.2 57,064 41.6
Good 529 38.2 44,693 32.6
Fair 267 19.3 10,637 7.7
Poor 47 3.4 900 0.7
History of treated diabetes 78 5.6 5,810 4.2 .010
History of stroke 79 5.7 1,687 1.2 <.001
History of multiple sclerosis (MS) 19 1.4 375 0.3 <.001
History of Parkinson’s disease 13 0.9 234 0.2 <.001
CT versus OS
a <.001
CT randomized 488 35.2 55,158 40.4
OS Enrolled 897 64.8 82,124 59.8
HT trial group .093
HT not randomized 1195 86.3 115,562 84.2
HT placebo 98 7.1 10,824 7.9
HT active 92 6.6 10,896 7.9
Dietary modification trial group .004
DM not randomized 1042 75.2 97,670 71.1
DM control 206 14.9 23,812 17.3
DM intervention 137 9.9 15,800 11.5
876 Journal of Bone and Mineral Research CARBONE ET AL.shown). There was no significant interaction between race/
ethnicity and total fractures (p¼.75) (data not shown).
Fracture and fall outcomes by number of AEDs used
In models adjusted for age, race/ethnicity, and BMI compared
with nonusers of AEDs, users of a single AED and more than one
AED were both at significantly higher risk for total fractures
(HR¼1.60, 95% CI 1.42–1.79 and HR¼2.68, 95% CI 2.04–3.53),
respectively; this persisted in fully adjusted models (HR¼2.68,
95% CI 2.04–3.53 and HR¼2.12, 95% CI 1.61–2.80, respectively;
see Table 4). In models adjusted for age, race/ethnicity, and BMI
andinfullyadjustedmodelsrespectively,HRscomparingthe150
participants who reported use of two or more AEDS with users of
a single AED (n¼1235) were significantly elevated for total
fractures (HR¼1.68, 95% CI 1.25–2.26 and HR¼1.55, 95% CI
1.15–2.09).
Fracture and fall outcomes by use of enzyme-inducing
and non-enzyme-inducing AEDs
In models adjusted for age, race/ethnicity, and BMI compared
with nonusers of AEDs, users of enzyme-inducing AEDs
(n¼681), non-enzyme-inducing AEDs (n¼663), and both
enzyme-inducing and non-enzyme-inducing AEDs(n¼41)were
at significantly higher risk for total fractures (HR¼1.44, 95% CI
Table 1. (Continued)
Antiepileptic users Nonusers
p Value n Mean (SD) or % N Mean (SD) or %
Calcium/vitamin D trial group .005
CaD not randomized 1136 82.0 107,698 78.5
CaD intervention 122 8.8 14,811 10.8
Total MET-hours/week of recreational
activity, mean (SD)
1385 11.25 (13.44) 137,282 12.57 (13.74) <.001
<2.3 409 29.5 34,093 24.8
2.3 to <8.4 341 24.6 34,407 25.1
8.4 to <18.5 348 25.1 35,194 25.6
 18.5 287 20.7 33,588 24.5
Baseline total vitamin D intake, mean IU/day (SD) 1385 393.0 (287.2) 137,282 374.7 (280.1) .015
<200 IU 488 35.2 51,035 37.2
200 to <400 IU 232 16.8 24,847 18.1
400 to <600 IU 370 26.7 34,503 25.1
 600 IU 295 21.3 26,897 19.6
Baseline total calcium intake, mean (SD) 1385 1227.6 (761.1) 137,282 1191.2 (748.1) .071
<800 mg 451 32.6 46,300 33.7
800 to <1200mg 331 23.9 33,609 24.5
 1200mg 603 43.5 57,373 41.8
Height, cm, mean (SD) 1385 162.16 (6.25) 137,282 161.87 (6.48) .094
Weight, kg, mean (SD) 1385 73.58 (16.61) 137,282 73.04 (16.09) .221
Body-mass index (BMI), kg/m
2, mean (SD) 1385 27.99 (6.22) 137,282 27.87 (5.91) .443
Age at menopause, years, mean (SD) 1385 46.56 (7.09) 137,282 48.11 (6.40) <.001
Table 2. Baseline Medication Use in Study Population by Antiepileptic Drug Use
Anticonvulsant users
(n¼1385) Nonusers (n¼137,282)
p Value n % N %
HT use at baseline <.001
Never used 466 33.6 56,639 41.3
Past user 274 19.8 22,680 16.5
Current user 645 46.6 57,963 42.2
Bisphosphonate use 43 3.1 2,748 2.0 .004
Calcitonin use 9 0.6% 386 0.3% .010
Selective estrogen
receptor modulator
(SERM) use
1 0.1 38 0.0 .326
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1.85–4.93, respectively); this remained true in fully adjusted
models (HR¼1.20, 95% CI 1.02–1.42; HR¼1.64, 95% CI 1.42–
1.89; and HR¼2.10, 95% CI 1.28–3.43, respectively; see Table 4).
Compared with non-enzyme-inducing AED users (n¼663), in
models adjusted for age, race/ethnicity, and BMI, users of
enzyme-inducingAEDs (n¼681)were atsignificantlyhigherrisk
of total fractures (HR¼1.29, 95% CI 1.04–1.61). In fully adjusted
models, a similar increased risk of total fractures also was seen
(HR¼1.36, 95% CI 1.09–1.69, respectively). These results were
not materially changed when divalproex sodium, valproic acid,
and topiramate were included as enzyme-inducing rather than
as non-enzyme-inducing AEDs (data not shown).
BMD outcomes
In the subset of women with BMD, in fully adjusted models,
compared with nonusers of AEDs, users of AEDs had no
significant differences in percentage change from baseline to
year 3 BMD of the hip (p¼.312), spine (p¼.064), or total body
(p¼0.539; see Table 5).
Table 3. Fracture Incidence and Fall Frequency by Use of AEDs at Baseline
Number of Events Annual % Model 1
a HR
,c (95% CI) Model 2
b HR
,c (95% CI)
Hip fractures
Nonuser 1,532 0.15 1.00 1.00
User 30 0.29 1.98 (1.38–2.85) 1.51 (1.05–2.17)
<2 years 10 0.30 2.19 (1.18–4.08) 1.59 (0.85–2.97)
2 to 5 years 9 0.27 1.72 (0.89–3.32) 1.31 (0.68–2.53)
>5 years 11 0.31 2.07 (1.14–3.74) 1.63 (0.90–2.95)
Clinical vertebral fractures
Nonuser 2,355 0.22 1.00 1.00
User 49 0.48 2.15 (1.62–2.86) 1.60 (1.20–2.12)
<2 years 17 0.51 2.38 (1.48–3.84) 1.69 (1.05–2.73)
2 to 5 years 12 0.37 1.61 (0.91–2.85) 1.17 (0.66–2.07)
>5 years 20 0.56 2.45 (1.58–3.80) 1.92 (1.23–2.98)
Lower arm or wrist
Nonuser 5,034 0.48 1.00 1.00
User 74 0.72 1.52 (1.21–1.91) 1.40 (1.11–1.76)
<2 years 15 0.45 0.95 (0.57–1.58) 0.90 (0.54–1.49)
2 to 5 years 28 0.83 1.79 (1.23–2.60) 1.64 (1.13–2.38)
>5 years 31 0.87 1.79 (1.26–2.55) 1.63 (1.14–2.32)
Other clinical fractures
Nonuser 15,974 1.51 1.00 1.00
User 256 2.49 1.73 (1.53–1.96) 1.46 (1.29–1.65)
<2 years 86 2.56 1.76 (1.42–2.17) 1.48 (1.19–1.83)
2 to 5 years 71 2.11 1.44 (1.14–1.82) 1.21 (0.96–1.53)
>5 years 99 2.79 1.99 (1.63–2.42) 1.69 (1.38–2.06)
Total fractures
Nonuser 22,137 2.10 1.00 1.00
User 344 3.35 1.70 (1.53–1.89) 1.44 (1.30–1.61)
<2 years 107 3.18 1.60 (1.32–1.93) 1.36 (1.12–1.64)
2 to 5 years 103 3.06 1.53 (1.26–1.85) 1.29 (1.07–1.57)
>5 years 134 3.78 1.96 (1.66–2.33) 1.68 (1.42–1.99)
Two or more falls
Nonuser 45,246 4.29 1.00 1.00
User 760 7.40 2.15 (2.00–2.31) 1.62 (1.50–1.74)
<2 years 257 7.65 2.23 (1.97–2.52) 1.58 (1.40–1.79)
2 to 5 years 239 7.10 2.05 (1.80–2.33) 1.55 (1.36–1.76)
>5 years 264 7.44 2.16 (1.92–2.44) 1.71 (1.52–1.94)
aModel 1 adjusted for age, ethnicity, BMI, and WHI trial participation and intervention.
bModel 2 adjusted for age, race/ethnicity, BMI, smoking, alcohol, calcium and vitamin D intake, history of fractures (fracture at age 55þ), history of falls
(two or more in the year prior to enrollment), bisphosphonates, past/current use of HT, SERMs, calcitonin, age of menopause, physical activity levels,
physical function construct, diabetes, stroke, parental history of hip fractures, study site region, self-reported health, multiple sclerosis, Parkinson’s, WHI
trial participation and intervention.
bcNonusers of AEDs are the reference group for both the any-use and the duration models.
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In this largest prospective study of AED use and osteoporosis in
multiethnic postmenopausal women, AEDs were associated
with a significantly increased risk for total and site-specific
fractures,includingbothnonvertebral(including hip)andclinical
vertebral fractures. The risk for fractures was a function of the
number and type of AEDs used, with women who used more
than one AED as opposed to single AED use and those who used
enzyme-inducing AEDs as opposed to the more recently
introduced non-enzyme-inducing AEDs more likely to fracture.
There was no significant association of AED use with BMD
changes;there was,however, asignificantassociation ofAEDuse
with falls.
The more than 1300 postmenopausal women AED users in the
WHI is the largest cohort of ambulatory, noninstitutionalized,
multiethnic women ever prospectively examined for fractures.
Although an elevated risk for total fractures has been reported
previously in AED users, these studies were limited by the
inability to control for potential confounders
(5,7,11) that we were
able to consider in the WHI.
Over 11% of our population (>200 AED users) were of racial
groups other than white (predominantly black), and the
increased risk of total fractures in these women was similar to
that of white women. This is potentially important because
seizures, a major indication for use of AEDs, occur across all racial
groups,
(9) and the relationship between AED use and fractures in
multiracial groups has not, to our knowledge, been explored
previously. Others have suggested that black race is an
independent risk factor for receipt of use of the older,
enzyme-inducing AEDs.
(38)
Relative to site-specific fractures, in agreement with our study,
some,
(7,8) but not all,
(6) studies report an elevated risk for hip
fractures with AED use, although these studies, in contrast with
Table 5. Mean Bone Mineral Density (BMD, g/cm
2 SE) and % Changes SE in Mean BMD by Current AED Use
Antiepileptic user Nonuser
p Value
a p Value
b (adjusted) n Mean
a (SE) n Mean
  (SE)
Initial measurement
Total hip 83 0.84 (0.017) 8644 0.87 (0.007) .096 .224
Total spine 82 0.96 (0.020) 8392 0.98 (0.008) .276 .647
Total body 83 1.01 (0.013) 8645 1.02 (0.005) .304 .777
Final measurement
Total hip 60 0.86 (0.020) 7222 0.89 (0.008) .127 .289
Total spine (final) 60 0.98 (0.025) 7017 1.01 (0.010) .097 .308
Total body (final) 60 1.01 (0.016) 7190 1.04 (0.006) .095 .229
3-Year BMD change
% Change in total hip 58 0.52 (0.576) 7141 1.24 (0.220) .180 .312
% Change in total spine 58 4.15 (0.730) 6962 2.91 (0.283) .067 .064
% Change in total body 57 1.34 (0.535) 7119 1.42 (0.203) .870 .539
aAdjusted for WHI trial participation and intervention.
bAdjustedforage,race,BMI,smoking,alcohol,calciumandvitaminDintake,historyoffractures(fractureatage55þ),historyoffalls(twoormoreinyear
prior to enrollment), bisphosphonates, past/current use of HT, SERMs, calcitonin, age of menopause, physical activity levels, physical function construct,
diabetes, stroke, parental history of hip fractures, study site region, self-reported health, multiple sclerosis, Parkinson’s, WHI trial participation, and
intervention.
Table 4. Relationship of AED Use With Total Fractures by Number and Type of AED Used
Events Annual % Model 1 HR (95% CI)
a Model 2 HR (95% CI)
b
Nonuser 22,137 2.10 1.00 1.00
Single AED user 293 3.18 1.60 (1.42–1.79) 1.37 (1.22–1.54)
Multiple AED user 51 4.75 2.68 (2.04–3.53) 2.12 (1.61–2.80)
Non-enzyme AED user 138 2.86 1.44 (1.22–1.71) 1.20 (1.02–1.42)
Enzyme AED user 190 3.69 1.87 (1.62–2.15) 1.64 (1.42–1.89)
Both AED type user 16 5.39 3.02 (1.85–4.93) 2.10 (1.28–3.43)
aModel 1 adjusted for age, ethnicity, BMI, and WHI trial participation and intervention.
bModel 2 adjusted for age, race/ethnicity, BMI, smoking, alcohol, calcium and vitamin D intake, prevalent fractures (fracture at age 55þ), prevalent falls
(two or more in the year prior to enrollment), bisphosphonates, past/current use of HT, SERMs, calcitonin, age of menopause, physical activity levels,
physical function construct, diabetes, stroke, parental history of hip fractures, study site region, self-reported health, MS, Parkinson’s, and WHI trial
participation and intervention.
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(6–8)
In accord with our results, an increased risk for Colles’ fracture
with AED use has been documented.
(7,39) The relationship
between AED use and vertebral fractures is more controversial,
with one study, similar to ours, reporting an approximately 50%
increased relative risk for vertebral fractures with AED use,
(7)
whereas another study found no significant relationship
between AED use and vertebral fractures.
(39) Our study differs
from those,
(7,39) however, in that we included only clinical
vertebral fractures.
In the WHI, both the number (more than one compared with
one) and type (enzyme-inducing compared with non-enzyme-
inducing) of AED used were significantly associated with
fractures. In agreement with this, one study
(7) found that
relative to non-enzyme-inducing AEDs, enzyme-inducing AEDs
weremore likely tobe associated with fractures. However, others
have noted no difference in the relationship between the type of
AED used and fracture risk.
(38) Although we were not able to
explore the mechanisms by which enzyme-inducing AEDs were
associated with more fractures than non-enzyme-inducing AEDs
in our study, we suspect that this may have been driven by
differences in 25-hydroxyvitamin D levels [25(OH)D], which we
did not have measurements of. Differences in 25(OH)D levels
between enzyme-inducing AEDs and non-enzyme-inducing
AEDs may have been particularly important because this could
have had an impact on both BMD
(40) and recurrent falls.
(41)
Cross sectionally, in the WHI there were no significant
differences in BMD between the 113 women who used AEDs
and the nonusers of AEDs. In contrast, other cross-sectional
studies have reported lower BMDs of the lumbar spine and hip
with AED use.
(40–42) Similarly, in the WHI, differences in fracture
rates between AED users and nonusers were not explained by
longitudinal differences in changes in BMD. However,
significant rates of bone loss at the hip in both women
(22)
and men
(43) AED users have been reported by others. The
reasons for these differences in findings in BMD in users of
AEDs in the WHI compared with these other studies are not
clear. It is possible that it is because only a subset of AED users
(84 women) over a limited time (3 years) had BMD measured,
limiting our power to detect BMD differences between the
groups. This BMD population was slightly older and had a
larger percentage of minority women than the whole cohort.
Another important mechanism that may underlie the relation-
ship of AED use and fractures is changes in bone metabolism;
however, biomarkers of bone metabolism were not available
for this entire cohort. Alternatively, it is possible that AEDs
i n c r e a s et h er i s ko ff r a c t u r es o l e l yb yi n c r e a s i n gf a l l sa n dh a v e
no effects on either BMD or biomarkers. If so, this may operate
in several ways. The first mechanism would be a direct result of
the AED itself increasing falls because dizziness, ataxia, and
unsteady gait are among the most common side effects of
AEDs.
(23–26)Thesecondpotentialmechanismwouldnotbeasa
direct effect of the AED by rather confounding by indication
b e c a u s ea ni n c r e a s i n gn u m b e ro ff a l l sm a yo c c u ri nm e d i c a l
conditions for which AEDs are used.
(1)
There are a number of limitations to our study. Although we
adjusted for conditions including diabetes, multiple sclerosis,
and Parkinson’s disease in which AEDs may be used, we did not
have information on seizure history, and seizures may be
associated with fractures.
(39) In addition, doses of AEDs were not
captured in the WHI. Prefracture health, which may change
precipitously in older populations, is a predictor of fracture,
(42,43)
and we only included baseline levels of prefracture health as a
covariateinthemodels.25(OH)DmaybeassociatedwithBMD
(44)
and AED use,
(15) but we could not adjust for this. The limited
number of women who had DXAs may have contributed to our
inability to show an association between AEDs and BMD.
Inconclusion, there was a significant association between AED
use andfallsand fracturesinmultiracial postmenopausal women
in the WHI. The risk for total fractures and all site-specific
fracturesincludingnonvertebral(andspecificallyhip)andclinical
vertebral fractureswassignificantlyhigher inAEDusers.Enzyme-
inducing AEDs were associated with the highest fracture risk.
Whether the association of AED with fractures is a function of the
drug itself or rather the condition for which it is being prescribed
merits further study. In clinical practice, however, postmeno-
pausal women who use AEDs should be considered at risk for
fracture, and attention to fall prevention in these women may be
particularly important.
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